MedWatch: The FDA Safety Information and Adverse Event Reporting Program
Newsletter which provides an FDA gateway for finding clinically important safety information and reporting serious problems with human medical products.
Free
Pharmacogenomics: Increasing the safety and effectiveness of drug therapy (electronic brochure)
The AMA, in collaboration with the Critical Path Institute and the Arizona Center for Education and Research on Therapeutics, developed a brochure intended for physicians and other health care providers who may not have extensive experience with pharmacogenomics,and introduces the concept using a case-based approach.
Free
Mastering Pharmacogenomics: A Nurse's Handbook for Success
Pharmacogenomics is the study of the role of genetics in drug response and has become a vital resources in battling disease and improving outcomes. As pivotal members of the healthcare team, nurses must acquire competency in pharmacogenomics to deliver optimal patient care in the 21st century.
Paid
A public health approach to pharmacogenomics and gene-based diagnostic tests
Link to an which presents the rationale for the development of one or more large clinical networks for the purpose of systematically evaluating the clinical effectiveness of new genomic applications including pharmaceuticals and gene based diagnostic tests in real world settings.
Free
Gene Tests - Laboratory Directory and Clinical Directory
Website which provides a listing of genetic testing laboratories and an international directory of genetics and prenatal diagnosis clinics, in addition to educational materials such as an illustrated glossary, information on genetic services, PowerPoint® presentations, annotated Internet resources.
Free
PharmGKB - The Pharmacogenomics Knowledge Base
Website designed to help researchers understand how genetic variations among individuals contribute to their differences in responses to drugs.
Free
Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants
Polymorphisms in CYP2D6 and CYP2C19 affect the efficacy and safety of tricyclics, with some drugs being affected by CYP2D6 only, and others by both polymorphic enzymes. Amitriptyline, clomipramine, doxepin, imipramine, and trimipramine are demethylated by CYP2C19 to pharmacologically active metabolites. These drugs and their metabolites, along with desipramine and nortriptyline, undergo hydroxylat...
Free
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for Cytochrome P450 2D6 (CYP2D6) genotype and codeine therapy
Codeine is bioactivated to morphine, a strong opioid agonist, by the hepatic cytochrome P450 2D6 (CYP2D6); hence, the efficacy and safety of codeine as an analgesic are governed by CYP2D6 polymorphisms. Codeine has little therapeutic effect in patients who are CYP2D6 poor metabolizers, whereas the risk of morphine toxicity is higher in ultrarapid metabolizers. The purpose of this guideline (period...
Free
FDA Preventable Adverse Drug Reactions: A Focus on Drug Interactions
A web-learning case which demonstrates why it is important that health care practitioners report ADRs to the Food and Drug Administration (FDA). This is also a pivotal case which resulted in recognition and definition of one type of preventable adverse drug reaction - drug interactions mediated by the cytochrome P450 pathway of drug metabolism. This module was developed by the Center for Education...
Free
Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping
Routine integration of genotype data into drug decision making could improve patient safety, particularly if many relevant genetic variants can be assayed simultaneously before prescribing the target drug. The frequency of opportunities for pharmacogenetic prescribing and the potential adverse events (AEs) mitigated are unknown. We examined the frequency with which 56 medications with known outcom...
.png)
No hay comentarios:
Publicar un comentario